Search bioRxiv⌕ Search

Biology subjects

Pietka, T.

Publications and source records attributed to Pietka, T..

2 recordsLinked to original sources

Immune cells regulate circulating adipocyte extracellular vesicle levels in response to metabolic shifts

Extracellular vesicles (EVs) are now recognized as potent mediators of intercellular and inter-organ signaling and implicated in the pathogenesis of obesity and its associated comorbidities such as diabetes, cancer, cardiovascular disease, and neurodegeneration. Despite a surge of new functional information about EVs, we still lack a basic understanding of how endogenous EV levels are controlled to regulate inter-organ signaling. New flow cytometry technology has allowed us to study the regulation of circulating, endogenous EVs from metabolically relevant cell types like adipocytes. From this, we provide evidence for a paradigm of EV regulation where tissue resident immune cells, predominantly macrophages, clear EVs released by local tissue cells or EVs entering the tissue from circulation, an activity that determines circulating EV levels. In obesity, EV uptake by adipose tissue immune cells is reduced, concomitant with increased circulating adipocyte-specific EVs (adipoEVs) and reduced EV clearance rates. AdipoEVs are significantly elevated in mouse circulation from one day to 20 weeks of high-fat feeding. In humans we found that adipocyte EV levels negatively correlate with whole-body and liver insulin sensitivity and are not associated with adipose mass. This work suggests that tissue resident immune cells act as a gatekeeper for tissue EV entry into circulation and are thereby a major regulator of inter-organ EV signaling.

physiology↗

Site-1 Protease inhibits mitochondrial metabolism by controlling the TGF-β target gene MSS51

The mitochondrial response to changes in cellular energy demand is necessary for cellular adaptation and organ function. Many genes are essential in orchestrating this response, including the transforming growth factor (TGF)-{beta}1 target gene MSS51, which is an inhibitor of skeletal muscle mitochondrial metabolism. Despite the potential importance of MSS51 in the pathophysiology of obesity and musculoskeletal disease, how MSS51 is regulated is not entirely understood. Site-1 Protease (S1P) is a Golgi-resident protease that is a key activator of several transcription factors required for cellular adaptation. However, the role of S1P in muscle and mitochondrial function are unknown. Here, we identify S1P as a negative regulator of muscle mass and mitochondrial metabolism. Disruption of S1P in mouse skeletal muscle and cultured myofibers leads to a reduction in MSS51 expression, increased muscle mass, and increased mitochondrial oxygen consumption. The effects of S1P deficiency on mitochondrial activity are counteracted by overexpressing MSS51, suggesting that S1P inhibits mitochondrial metabolism by regulating the expression of MSS51. Furthermore, S1P suppression enhances TGF-{beta} signaling via the AKT pathway, potentially explaining muscle hypertrophy in S1P deficient mice. The discovery of S1P as a regulator of mitochondrial metabolism and muscle mass expands our understanding of TGF-{beta} signaling and suggests this protease could be a target for therapeutic intervention in muscle.

molecular biology↗